Article
Molecular testing and personalized treatment of lung cancer.
Current molecular pharmacology - 1 Jan 2014
Sampsonas Fotis, Ryan Daniel, McPhillips Dympna, Breen David P
Abstract excerpt
Lung malignancy is a leading cause of cancer related morbidity and mortality worldwide. The majority (85%) of cases are histologically proven non-small cell lung carcinomas (NSCLC). More than 55% of lung carcinomas harbor at least one genetic alteration, most of them being histologic subtype specific. This review summarizes the progress in personalized care of lung cancer by reviewing the literature on EGFR, ALK...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
